Nucleai

Nucleai

Nucleai

Nucleai transforms immunotherapy treatment decisions and research by AI-powered Tumor Micro Environment (TME) modeling
Founded
2017
Raised
$11.5M
Follow us
Alexa global traffic share
Latest funding
$6,500,000
Venture capital (Series A) - 2020
Grove Ventures Vertex Ventures Debiopharm
$5,000,000
Seed fund - 2018
Grove Ventures Vertex Ventures Nir Kalkstein
Team Size
1–10
Employees
Location
Headquarters
neurons.AI

Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai’s Ai-Powered …

$6,500,000 Venture capital (Series A)
Verdict

Nucleai raises $6.5m to advance predictive oncology platform